Our findings provide valuable information about the function of KDM4 in controlling the innate sensing and immunogenicity of tumours, and propose a strong basis for combining KDM4 inhibition with anti‐PD‐1/PD‐L1 immunotherapy in cancer patients. The gene discussed is CD274; the disease is neoplasm.